| BDI | Beck Depression Inventory |
| BSI | Beck Scale for Suicidal Ideation |
| CI | Confidence Intervals |
| FACIT-Sp | Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale |
| FDA | U.S. Food and Drug Administration |
| GRADE | Grading of Recommendation Assessment, Development and Evaluation |
| GRID-HAMD-17 | GRID-Hamilton Depression Rating Scale |
| HAD-D | Hospital Anxiety and Depression Scale—Depression subscale |
| HADS-T | The Hospital Anxiety and Depression Scale—Total |
| HAM-D | Hamilton Depression Rating Scale |
| HAM-D-17 | 17-item Hamilton Depression Rating Scale |
| LSD | lysergic acid diethylamide |
| LTI | Life-threatening illness |
| MADRS | Montgomery-Asberg Depression Rating Scale |
| MADRS-SI | Montgomery–Åsberg Depression Rating Scale—Suicidal Ideation |
| MAPS | Multidisciplinary Association for Psychedelic Studies |
| MDD | Major Depressive Disorder |
| MDMA | 3,4-methylenedioxymethamphetamine |
| MDPI | Multidisciplinary Digital Publishing Institute |
| MEQ-30 | Mystical Experience Questionnaire |
| NIH | National Institute of Health |
| NIH-HEALS | National Institute of Health—Healing Experience of All Life Stressors |
| NMDA | N-methyl-D-aspartate |
| PAT | Psychedelic-assisted therapy |
| PHQ-9 | Patient-reported depression |
| PLWC | People living with cancer |
| PRISMA | preferred reporting items for systematic reviews and meta-analyses |
| RCT | Randomized controlled trials |
| RoB | Risk of bias |
| STAI | State-Trait Anxiety Inventory |